DossierENTITY

Kailera Therapeutics

Coverage of Kailera Therapeutics in the Nexus archive.

Earliest in view: Apr 17 · 17:41 UTCMost recent: Jun 10 · 16:21 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 10 · 16:21 UTCQUARTZ
Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO
Parabilis Medicines, a Cambridge, Massachusetts-based biotech, is raising $670 million in its IPO by pricing 33.5 million shares at $20 each, surpassing Kailera Therapeutics' previous record of $625 million raised in April.
BUSINESSApr 17 · 17:41 UTCBLOOMBERG
Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
Kailera Therapeutics, an obesity-focused biotech firm, saw its stock rise 63% on the New York Stock Exchange after a $625 million initial public offering (IPO). The surge highlights investor confidence in the company's potential in the weight-loss drug market.